Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapy

BACKGROUND: Nusinersen was the first approved disease-modifying therapy for all 5q-spinal muscular atrophy (SMA) patients regardless of age or disease severity. Its efficacy in adults has recently been demonstrated in a large cohort by motor outcome measures, which were only partially suitable to de...

Descripción completa

Detalles Bibliográficos
Autores principales: Osmanovic, Alma, Ranxha, Gresa, Kumpe, Mareike, Wurster, Claudia D., Stolte, Benjamin, Cordts, Isabell, Günther, René, Freigang, Maren, Müschen, Lars H., Binz, Camilla, Hermann, Andreas, Deschauer, Marcus, Lingor, Paul, Ludolph, Albert C., Hagenacker, Tim, Schreiber-Katz, Olivia, Petri, Susanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940734/
https://www.ncbi.nlm.nih.gov/pubmed/33747131
http://dx.doi.org/10.1177/1756286421998902

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940734/
https://www.ncbi.nlm.nih.gov/pubmed/33747131
http://dx.doi.org/10.1177/1756286421998902

Ejemplares similares